Overall, increasing VEGFA is broadly discussed as a therapeutic option for patients with DMD, with the intention of increasing angiogenesis and satellite cell activity; however, its efficacy is unknown (59, 60). The gene discussed is VEGFA; the disease is Duchenne muscular dystrophy.